Healthcare · NYSE/NASDAQ: EW
Edwards Lifesciences Corp
Medical Devices
Market Cap $49.68B
Verdict: High
Quality Scores
Multi-Bagger
82/100
Compounder Quality
94/100
Management Credibility
92/100
Governance
92/100
Cash Flow Quality
90/100
AI Summary
Edwards Lifesciences (EW) is a dominant global leader in patient-focused innovations for structural heart disease and critical care monitoring, most notably the TAVR (Transcatheter Aortic Valve Replacement) market. Over the last decade, the company has scaled from a niche cardiovascular player to a multi-billion dollar healthcare giant. Financial data shows significant revenue scaling, particularly between 2020 and 2021 where revenue jumped from $1.19B to $5.23B, reflecting aggressive market expansion and product adoption. Despite some volatility in operating margins and net income reporting…
Top Opportunities
- Market leader in Transcatheter Aortic Valve Replacement (TAVR)
- Virtually debt-free balance sheet
- Consistently high ROIC above cost of capital
Top Risks
- Increasing competitive pressure from Medtronic and Abbott
- Recent volatility in operating cash flows
- Pricing pressure in mature US and European markets
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.